Table 1 Baseline demographic and clinical characteristics of the population
Characteristic | Â | Before propensity score matching | Â | Â | After propensity score matching | Â | Â |
|---|---|---|---|---|---|---|---|
Total N = 431 (%) | Pfizer (n = 283) | AstraZeneca (n = 148) | p-value | Pfizer (n = 148) | AstraZeneca (n = 148) | p-value | |
Age (years) | 51.3 ± 16.2 | 53.2 ± 16 | 47.7 ± 15.9 | 0.0008 | 46.9 ± 15.9 | 47.7 ± 15.9 | 0.675 |
Sex | |||||||
 Male | 295 (68.4) | 197 (69.6) | 98 (66.2) | 0.504 | 102 (68.9) | 98 (66.2) | 0.619 |
BMI | 28.2 ± 5.6 | 28.1 ± 5.5 | 28.2 ± 5.7 | 0.930 | 27.5 ± 5.9 | 28.2 ± 5.7 | 0.345 |
Hypertension | 205 (47.5) | 126 (44.5) | 79 (53.3) | 0.080 | 87 (58.7) | 79 (53.3) | 0.349 |
Diabetes | 191 (44.3) | 126 (44.5) | 65 (43.9) | 0.905 | 52 (35.1) | 65 (43.9) | 0.122 |
Type of Tx | Â | Â | Â | 0.000 | Â | Â | 0.898 |
 Liver  Kidney | 201 (46.6) 230 (53.3) | 158 (55.8) 125 (44.1) | 43 (29) 105 (70.9) |  | 44(29.7) 104 (70.2) | 43 (29.05) 105 (70.95) |  |
Time since TX (years) | 7.35 [0.13–33.4] | 7.22 [0.13–33.4] | 7.62 [0.5–22.7] | 0.489 | 7.1 [0.13–33.4] | 7.6 [0.5–22.7] | 0.470 |
Tx < 1 year | 9 (2) | 8 (2.8) | 1 (0.6) | 0.138 | 3 (2.03) | 1 (0.68) | 0.314 |
Deaths | 6 (1.3) | 5 (1.7) | 1 (0.6) | 0.708 | 2 (1.35) | 1 (0.68) | 1.00 |
Prednisone | 289 (67) | 179 (63.2) | 110 (74.3) | 0.020 | 116 (78.3) | 110 (74.3) | 0.412 |
Tacrolimus | 408 (94.6) | 268 (94.7) | 140 (94.5) | 0.963 | 141 (95.2) | 140 (94.9) | 0.791 |
Mycophenolate | 305 (70.7) | 197 (69.6) | 108 (72.9) | 0.466 | 111 (75) | 108 (72.9) | 0.691 |
Triple regimen (TMP)a | 235 (54.5) | 146 (51.9) | 89 (60.14) | 0.091 | 94 (63.5) | 89 (60.1) | 0.550 |
Thymoglobulinb | 133 (57.8) | 76 (60.8) | 57 (54.2) | 0.31 | 64 (61.5) | 57 (54.2) | 0.288 |
Basiliximab | 45 (10.4) | 26 (9.1) | 19 (12.8) | 0.23 | 17 (11.4) | 19 (12.8) | 0.72 |